Immunomedics, Inc. appointed of Mr. Robert Azelby to the Board. On February 26, 2020, upon recommendation of the Governance and Nominating Committee of the Board of Directors of Immunomedics, Inc., the Board appointed Robert Azelby to serve as a director of the Company, effective immediately. Mr. Azelby, age 52, was most recently the President and Chief Executive Officer of Alder BioPharmaceutials, Inc. from June 2018 to November 2019. Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Cascadian Therapeutics, Inc. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.